ZEVRA THERAPEUTICS, INC.
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Non-accelerated filerSmaller reporting company
State of Incorporation
DE
Business Address
101 FEDERAL STREET, BOSTON, MA, 02110
Mailing Address
101 FEDERAL STREET, BOSTON, MA, 02110
Phone
(888) 958-1253
Fiscal Year End
1231
EIN
205894398
Financial Overview
FY2025
$138.46M
Total Liabilities
$154.66M
Stockholders' Equity
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| SCHEDULE 13G/A Passive ownership amendment | March 27, 2026 | View on SEC |
| 4 Insider stock transaction report | March 26, 2026 | View on SEC |
| 4 Insider stock transaction report | March 19, 2026 | View on SEC |
| 3 Initial insider ownership report | March 19, 2026 | View on SEC |
| 8-K Current report of material events | March 16, 2026 | View on SEC |
| 8-K Current report of material events | March 9, 2026 | View on SEC |
| 10-K Annual financial report | March 9, 2026 | View on SEC |
| 4 Insider stock transaction report | February 10, 2026 | View on SEC |
| 4 Insider stock transaction report | February 4, 2026 | View on SEC |
| 4 Insider stock transaction report | February 4, 2026 | View on SEC |
Annual Reports
10-K
March 9, 2026
- Successfully completed patient enrollment for the pivotal Phase 3 trial of Arimoclomol for Niemann-Pick disease Type C (NPC), with initial results expected in early 2027.
- Secured Orphan Drug Designation and Fast Track designation from the FDA for ZVRA-101, alongside a strategic collaboration agreement for a pipeline candidate in Europe.
Material Events
8-K
Strategy Change
March 16, 2026
High Impact
- Strategic pivot to a pure-play rare disease company, focusing on arimoclomol and SDX for narcolepsy.
- Eliminated approximately $63 million in outstanding term loan debt, significantly strengthening the balance sheet.
Insider Trading
STRONG SELL
5 insiders
8 recent transactions
View Full Insider Trading Profile
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.